CHRI curates and manages a searchable library of published scientific articles related to the health effects of cannabis.
Unfamiliar with a term?
Use the Search Fields to Find Information
This library aims to empower you with knowledge but it does not replace the personalized advice and guidance a healthcare professional can provide. Before implementing any changes to your health regimen based on the contents of this library, we strongly advise you to consult with a qualified healthcare professional. Your doctor’s expertise is essential for interpreting how these insights may apply to your unique health circumstances.
Found 2431 Results
Page 10 of 244
Tolerability of High-Dose Oral Δ9-THC: Implications for Human Laboratory Study Design
Please use this link to access this publication. Abstract Background: Δ9-tetrahydrocannabinol (THC), the primary intoxicating compound in cannabis, has been tested extensively in controlled administration human studies. Some studies require a…
Tissue Engineering of Cartilage; Can Cannabinoids Help?
This review discusses the role of the cannabinoid system in cartilage tissue and endeavors to establish if targeting the cannabinoid system has potential in mesenchymal stem cell based tissue-engineered cartilage…
Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
Abstract Objective We conducted a post hoc analysis of two randomized controlled trials, GWPCARE1 (NCT02091375) and GWPCARE2 (NCT02224703), to estimate the time to onset of cannabidiol (CBD) treatment effects (seizure…
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
Abstract Objective To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of GWPCARE6 (NCT02544763), a randomized, placebo-controlled,…
Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
Abstract Objective To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo-controlled, Phase…
Thymol modulates the endocannabinoid system and gut chemosensing of weaning pigs
Abstract Background The recent identification of the endocannabinoid system in the gastrointestinal tract suggests a role in controlling intestinal inflammation. In addition, the gut chemosensing system has therapeutic applications…
Thymol has beneficial effects on the experimental model of ulcerative colitis
Abstract Objective: Thymol, a natural aromatic monoterpene phenol derived from thymus, possesses anti-inflammatory benefits. Here, we evaluated the potential of thymol therapy in improving an animal model of ulcerative colitis….
Thromboembolic Outcomes in Tetrahydrocannabinol-Positive Trauma Patients With Traumatic Brain Injury
Please use this link to access publication Abstract Introduction Traumatic brain injury (TBI) is a significant source of morbidity and mortality in the United States. Recent shifts in state legislation…
Therapeutical use of the cannabinoids in psychiatry
Objective: To review the main advances related to the potential therapeutic use of cannabinoid compounds in psychiatry. Method: A search was performed in the online databases PubMed, ScieELO, and Lilacs…
Therapeutic use of medical Cannabis in neurological diseases: a clinical update
Abstract The use of medical Cannabis has increased in recent years due to changing legal circumstances in many countries. Approval exists only for a few neurological conditions such as rare forms of…
CHRI aims to inform clinical decision-making, product development and public policy related to the therapeutic use of cannabinoids.